Focus Stocks
New Analyst Coverage
Published on Friday, 13 July 2012 08:16 Written by Danny Miller
New York, July 13th (TradersHuddle.com) – Following are some of the new analyst ratings before the market open.
Research Firms Initiate:
Albemarle (NYSE: ALB) was initiated with Overweight at Piper Jaffray.
Corcept Therapeutics (NASDAQ: CORT) was initiated with Underperform at Bank of America Merrill.
Fabrinet (NYSE: FN) was initiated with a Hold at Needham.
Finisar (NASDAQ: FNSR) was initiated with a Hold at Needham.
Gen Growth Properties (NYSE: GGP) was initiated with a Market Perform at Wells Fargo.
Google (NASDAQ: GOOG) was initiated with a Neutral at Wedbush.
HeartWare (NASDAQ: HTWR) was initiated with a Neutral at Goldman Sachs.
JDS Uniphase (NASDAQ: JDSU) was initiated with a Hold at Needham.
Macerich (NYSE: MAC) was initiated with a Market Perform at Wells Fargo.
NetSuite (NYSE: N) was initiated with a Hold at ThinkEquity.
Oclaro (NASDAQ: OCLR) was initiated with a Hold at Needham.
PVH Corp. (NYSE: PVH) was initiated with a Buy at Lazard.
Salesforce.com (NYSE: CRM) was initiated with a Buy at ThinkEquity.
Related Articles
- Albemarle to release second quarter 2013 earnings results on July 17, 2013
- Gerald Steiner elected to Albemarle board
- General Growth Properties to Webcast Management Presentation at REITWeek 2013
- Albemarle to increase prices of dibromomethane and bromochloromethane
- Silver Jeans Co.™ Heads To The Woodlands, Texas For Its First Retail Location
- Bloomingdale's To Open At Ala Moana Center
- GGP and TIAA-CREF Enter Partnership to Own The Grand Canal Shoppes
- Albemarle and Senze Meilu form mineral flame retardant joint venture
- GGP Declares Common and Preferred Dividends
- Albemarle announces quarterly dividend
Related Partner Headlines
- Albemarle Corp (ALB): Today's Featured Chemicals Winner - TheStreet.com
- UPDATE: JP Morgan Downgrades Fabrinet to Neutral on Valuation - Benzinga
- UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Underweight on Competitive Concerns - Benzinga
- UPDATE: Oppenheimer Downgrades Corcept Therapeutics to Perform on Disappointing Sales - Benzinga
- Albemarle Corp (ALB): Today's Featured Chemicals Winner - TheStreet.com
- UPDATE: Piper Jaffray Reduces PT to $67 on Albemarle on Bromine Derivatives Visibility - Benzinga
- UPDATE: Stifel Nicolaus Reduces PT to $18 on Finisar on Competitor Pre-Announcement - Benzinga
- At The Right Price, Albemarle Would Be A Great Idea (ALB, CHMT, GRA, RDS.A, AAPL) - Investopedia
- UPDATE: J.P. Morgan Reiterates Overweight Rating, Lowers PT on Albemarle Corporation - Benzinga
- UPDATE: Morgan Stanley Initiates Albemarle Corporation at Equal-Weight on Electronics Exposure - Benzinga
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
